Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of AVAXIM 80U-Pediatric Alone or with TRIMOVAX in 12–13 Month-Old Turkish Children
2015-005192-24Phase 4
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of Avaxim Junior in hepatitis A (HAV), measles, mumps and 1 more (2 arms), sponsored by Sanofi. Primary endpoints: Seroprotection rate at Day 28 and Immunogenicity of hepatitis A vaccine in pediatric recipients.
02
Drugs
Avaxim Junior
03
Conditions
hepatitis A (HAV)measlesmumpsrubella
Beyond the preview
Go deeper on 2015-005192-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005192-24.